Xaira Therapeutics

Launched in 2024 with over $1 billion to build AI-native drug discovery from Baker-lab protein design.

Co-founded with David Baker and Marc Tessier-Lavigne; integrates de novo protein design, large-scale perturbation biology, and antibody generation.

Headquarters